stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Debt to equity
Cytokinetics, Incorporated's debt to equity at the end of the quarter to 30 September 2026 was −0.5×, up 1.2× from fiscal 2025 (−1.8×). Over the past ten years it has ranged from −12.3× (fiscal 2019) to 1.6× (fiscal 2018); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −1.8× | — |
| FY2024 | −4.9× | — |
| FY2023 | −1.6× | — |
| FY2022 | −5.7× | — |
| FY2021 | 0.6× | (47.10%) |
| FY2020 | 1.2× | — |
| FY2019 | −12.3× | — |
| FY2018 | 1.6× | 465.30% |
| FY2017 | 0.3× | (8.65%) |
| FY2016 | 0.3× | 48.41% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −0.5× | — |
| Jun 2026 | −6.6× | — |
| Mar 2026 | −1.4× | — |
| Dec 2025 | −1.8× | — |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CYTK Cytokinetics, Incorporated | −0.5× |
| KRYS Krystal Biotech, Inc. compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| SYRE Spyre Therapeutics, Inc. compare | 0.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 0.0× |
| CORT Corcept Therapeutics Incorporated compare | 0.0× |
| TWST Twist Bioscience Corporation compare | 0.0× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.5× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 1.9× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement